JANX007

Why Janux Therapeutics Shares Rose 33.1% This Week
Motley Fool
Sun, 10/23/22 - 06:56 pm
Janux Therapeutics
oncology
JANX007
clinical trials
metastatic castration-resistant prostate cancer
Janux doses first subject in Phase I prostate cancer therapy trial
Clinical Trials Arena
Thu, 10/13/22 - 09:43 am
Janux Therapeutics
JANX007
prostate cancer
clinical trials